Premium
SELDI‐TOF‐MS combined with LCM as a screening technique for cancer biomarkers
Author(s) -
Zhao Xiangrong
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.596
Subject(s) - laser capture microdissection , biomarker discovery , proteomics , cancer , pathology , prostate cancer , cancer biomarkers , biomarker , metastasis , biology , medicine , cancer research , gene , biochemistry , gene expression
Proteomics helps the discovery of new biomarkers for the early detection, diagnosis, therapeutics, and prognosis of diseases, including cancers. Laser capture microdissection (LCM) isolates pure populations of cells directly from the paraffin‐embedded or frozen tissue sections, while preserving the exact morphologies of both the captured and surrounding cells. The small quantities of tissue obtained by LCM can be further analyzed by the surface‐enhanced laser desorption/ionization time‐of‐flight (SELDI‐TOF) ProteinChip array coupled with mass spectroscopy (MS). The highly sensitive and specific SELDI‐TOF‐MS technique rapidly identifies great numbers of low abundance proteins which are differentially expressed among defined cell populations. Here we present the meta‐analysis of LCM‐SELDI studies reported to date in human breast cancer, ovarian cancer, prostate cancer, and other endocrine system tumors, including samples from both clinicopathological specimens and selected cell lines. The effectiveness of LCM‐SELDI technique in cancer biomarker screening is evidenced by the correlations between unique protein peaks and corresponding histological/clinical features in differential sample populations, such as in benign, pre‐neoplasia, cancer, and malignant metastasis tissues.